Edition:
United States

AbbVie Inc (ABBV.K)

ABBV.K on New York Consolidated

94.47USD
22 Nov 2017
Change (% chg)

$-0.21 (-0.22%)
Prev Close
$94.68
Open
$94.69
Day's High
$95.40
Day's Low
$94.22
Volume
2,560,662
Avg. Vol
6,257,113
52-wk High
$98.26
52-wk Low
$58.60

Latest Key Developments (Source: Significant Developments)

Amgen and AbbVie agree to settlement allowing commercialization of Amgevita
Thursday, 28 Sep 2017 08:00am EDT 

Sept 28 (Reuters) - Amgen Inc :Amgen and AbbVie agree to settlement allowing commercialization of Amgevita.Amgen Inc - Amgen expects to launch Amgevita in Europe on Oct. 16, 2018, and Amjevita in United States on Jan. 31, 2023.​.Says to begin launching biosimilar adalimumab in Europe in 2018​​.Amgen Inc - ‍under terms of agreement, AbbVie will grant patent licenses for use and sale of Amgevita/Amjevita worldwide, on a country-by-country basis​.Says Amgen and AbbVie have agreed to dismiss all pending litigation​.Says ‍specific financial terms of agreement were not disclosed​.  Full Article

Enanta says Abbvie’s Maviret approved in Japan for the treatment of all major genotypes of chronic hepatitis c
Wednesday, 27 Sep 2017 06:30am EDT 

Sept 27 (Reuters) - Enanta Pharmaceuticals Inc :Enanta announces that Abbvie’s Maviret (glecaprevir/pibrentasvir) received approval in Japan for the treatment of all major genotypes (GT1-6) of chronic hepatitis c.Enanta Pharmaceuticals - co expects to receive $15 million milestone payment from Abbvie in quarter ending Dec 31, 2017, upon price reimbursement approval of Maviret in Japan​.Enanta Pharma - expects to get $15 million milestone payment from Abbvie in quarter ending Dec 31, 2017, upon Japan​ price reimbursement approval of Maviret.Enanta Pharmaceuticals -‍in Japan, Maviret is also approved as 12-week option for patients infected with GT3-6, patients with specific challenges​.  Full Article

AbbVie announces approval of Maviret for chronic hepatitis C treatment in Japan
Wednesday, 27 Sep 2017 12:54am EDT 

Sept 27 (Reuters) - Abbvie Inc :AbbVie announces approval of Maviret (glecaprevir/pibrentasvir) for the treatment of chronic hepatitis C in all major genotypes (GT1-6) in Japan.Approval is supported by a 99 percent virologic cure rate in patients.  Full Article

AbbVie and Bristol-Myers Squibb announce clinical research collaboration to evaluate a therapeutic regimen in advanced solid tumors
Friday, 22 Sep 2017 06:59am EDT 

Sept 22 (Reuters) - AbbVie Inc :AbbVie and Bristol-Myers Squibb announce clinical research collaboration to evaluate a therapeutic regimen in advanced solid tumors.Bristol-Myers Squibb Co - ‍specific terms of agreement were not disclosed.​.Bristol-Myers Squibb Co - ‍AbbVie is sponsor conducting trial​.Bristol-Myers Squibb Co - ‍study could expand into additional solid tumors in future​.Bristol-Myers - collaboration to evaluate combination of abbVie's ABBV-399 and co's Opdivo in c-Met overexpressing non-small cell lung cancer​.  Full Article

AbbVie announces positive topline results from phase 3 trial evaluating Venclexta/Venclyxto tablets in combination with Rituxan
Monday, 18 Sep 2017 11:30am EDT 

Sept 18 (Reuters) - AbbVie Inc ::AbbVie announces positive topline results from phase 3 trial evaluating Venclexta™/Venclyxto™ (Venetoclax) tablets in combination with Rituxan® (Rituximab) for the treatment of patients with relapsed/refractory chronic lymphocytic Leukemia.Abbvie Inc - ‍Phase 3 Murano Study Of Venclexta venclyxto tablets in combination with rituxan met its primary endpoint​.Abbvie inc - ‍Venclexta/Venclyxto is being developed by AbbVie and Roche​.AbbVie Inc - ‍Safety data, including serious and most common adverse events and discontinuation rates, are currently being analyzed​.AbbVie - ‍Tumor lysis syndrome, including fatal events, has occurred in patients with previously treated CLL with high tumor burden on treating with Venclyxto​.  Full Article

AbbVie's upadacitinib meets all primary and ranked secondary endpoints
Monday, 11 Sep 2017 08:02am EDT 

Sept 11 (Reuters) - AbbVie Inc ::AbbVie's upadacitinib (ABT-494) meets all primary and ranked secondary endpoints in second phase 3 study in rheumatoid arthritis.AbbVie Inc - ‍safety profile of upadacitinib was consistent with previously reported studies, with no new safety signals detected​.AbbVie - ‍Select-beyond showed positive results with both doses (15 mg, 30 mg once-daily) meeting primary endpoints in difficult-to-treat patient population​.AbbVie Inc - ‍phase 3 trials of upadacitinib in psoriatic arthritis are ongoing​.  Full Article

Abbvie Inc says sets quarterly cash dividend of $0.64/shr
Friday, 8 Sep 2017 11:03am EDT 

Sept 8 (Reuters) - Abbvie Inc :Says ‍board of directors of Abbvie Inc declared a quarterly cash dividend of $0.64 per share​.Says Since 2013, Abbvie has increased its dividend by 60 percent .  Full Article

Coherus Biosciences says ‍PTAB denied 4 petitions for inter partes review of Abbvie's patent
Thursday, 7 Sep 2017 11:57am EDT 

Sept 7 (Reuters) - Coherus Biosciences Inc :Coherus Biosciences provides update on ‘619 IPR institution decision.Says ‍PTAB denied institution of all 4 petitions for inter partes review of Abbvie's patent related to Abbvie's Humira formulation​.  Full Article

Abbvie's upadacitinib meets primary endpoint in phase 2b study in atopic dermatitis
Thursday, 7 Sep 2017 08:03am EDT 

Sept 7 (Reuters) - Abbvie Inc :Abbvie's upadacitinib (abt-494) meets primary endpoint in phase 2b study in atopic dermatitis.Abbvie Inc - "‍look forward to advancing upadacitinib to phase 3 studies in 2018"​.Abbvie Inc - ‍upadacitinib is not approved by regulatory authorities and safety and efficacy have not been established​.Abbvie-‍results showed that primary, secondary endpoints, patients treated with upadacitinib achieved improvements that were statistically significant.Abbvie Inc - ‍in study, no new safety signals were detected​.  Full Article

Abbvie submits NDA to U.S. FDA for investigational oral treatment Elagolix for management of endometriosis with associated pain
Wednesday, 6 Sep 2017 08:01am EDT 

Sept 6 (Reuters) - Abbvie Inc ::Abbvie submits new drug application to U.S. FDA for investigational oral treatment Elagolix for the management of endometriosis with associated pain.Abbvie Inc - ‍submitted NDA to U.S. Food and drug administration for Elagolix​.  Full Article

Roche, AbbVie leukemia drug superior to older medicine in study

Patients with a type of leukemia that had relapsed who received the new drug Venclexta in combination with Rituxan went significantly longer without the disease worsening than those treated with Rituxan and Treanda, according to interim results from a pivotal late stage study released on Tuesday.